Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

33%

2 of 6 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

N/A

4(66.7%)

Phase 3

2(33.3%)

6Total

N/A(4)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT05148845Phase 3Unknown

Sisonke 2 - A COVID-19 Vaccine Boost Open Label Study.

Role: collaborator

NCT04838795Phase 3Completed

Sisonke (Together): OPEN LABEL TRIAL COVID-19

Role: collaborator

NCT03271307Not ApplicableCompleted

Use of HIV Self-Test Kits to Increase Identification of HIV-Infected Individuals and Their Partners

Role: collaborator

NCT03101592Not ApplicableTerminated

INTERVAL: Varying Intervals of ART to Improve Outcomes in HIV

Role: collaborator

NCT03809741Not ApplicableCompleted

Intervention Zambia Rural L&D Infection Study

Role: collaborator

NCT04038320Completed

Simplified Antiviral Treatment Strategy for Hepatitis C in Ukraine

Role: lead

NCT03579576Completed

Simplified Antiviral Treatment Strategy for Hepatitis C in Myanmar

Role: lead

NCT02620436Not ApplicableCompleted

Impact Evaluation of Maternity Homes Access in Zambia

Role: collaborator

All 8 trials loaded